Key facts
- A U.S. biotechnology company specializing in therapies for infant brain injuries intends to list on the Hong Kong Stock Exchange.
- The company aims to leverage the Hong Kong market for capital raising and expansion into Asia.
A U.S. biotechnology company that is developing therapies for infant brain injuries is planning to list on the Hong Kong Stock Exchange. The move is intended to access capital markets in Asia and potentially fund further research and development for its treatments.